GleamWall
中文EN

CBIH Cannabis Bioscience International Holdings, Inc.

Services-Commercial Physical & Biological Research · OTC · SEC CIK 1411057 · Fiscal year ends 05/31

Financial factors as of 2026-02-28 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-64.1%
TTM net income YoY-8.9%
TTM EPS YoY-461.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin78.8%
Operating margin-322.6%
Net margin-416.8%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-6,272.5%
ROIC (approx.)—
Asset turnover15.05x

Leverage & solvency

Liabilities / assets95,121.4%
Debt / equity—
Current ratio0.00x
Interest coverage-2.68x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-3,008.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-02-282026Q22025-11-302026Q12025-08-312025Q4*2025-05-312025Q32025-02-282025Q22024-11-302025Q12024-08-312024Q4*2024-05-31
Income statement
Revenue$11,205$53,266$24,200$34,956$14,931$74,248$178,887$75,862
Cost of revenue$3,045$10,500$8,143$4,545$19,396$7,803$8,362$9,878
Gross profit$8,160$42,766$16,057$30,411-$4,465$66,445$170,525$65,984
SG&A expense$26,828$30,972$23,308-$49,690$50,172$40,128$61,296$9,747
Operating income-$93,259-$95,877-$74,784-$134,900-$129,234-$59,627-$97,604-$29,634
Interest expense$10,776$17,860$17,368$102,749$22,473$8,701$2,339$95,302
Net income-$103,933-$116,966-$82,645-$211,744-$181,243-$79,528-$76,305-$135,935
EPS (basic)-0.00-0.00-0.00—-0.00-0.00-0.00—
EPS (diluted)-0.00-0.00-0.00—-0.00-0.00-0.00—
Weighted avg. shares (diluted)11.63B11.63B11.63B—10.73B10.50B10.46B—
Balance sheet
Cash & equivalents$90$132$223$12,952$548$1,002$969$755
Receivables$1,266$21,811$8,966$6,380$2,640—$17,176$20,139
Current assets$1,544$22,131$18,942$29,085$3,786—$18,743$21,492
Total assets$1,544$22,131$18,942$31,880$14,886—$46,280$57,162
Current liabilities$1.22M$1.14M$1.02M$945,963$970,058—$852,097$881,909
Short-term debt$14,592$14,952$14,952$14,592$14,592—$7,054$7,054
Long-term debt$249,500$249,500$249,500$249,500$249,501—$249,500$249,361
Total debt$264,092$264,452$264,452$264,092$264,093—$256,554$256,415
Total liabilities$1.47M$1.39M$1.27M$1.20M$1.24M—$1.10M$1.14M
Shareholders' equity-$1.47M-$1.36M-$1.25M-$1.16M-$1.23M-$1.13M-$1.06M-$1.08M
Net debt$264,002$264,320$264,229$251,140$263,545—$255,585$255,660
Shares outstanding11.63B11.63B11.63B11.63B10.93B—10.56B10.43B
Cash flow statement
Operating cash flow-$14,597-$5,493-$103,712-$144,312-$82,812-$72,090-$30,413-$174,439
Financing cash flow———$156,716——$30,627$174,400

Free plan shows the latest 8 periods; Pro shows all 21 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.